Show simple item record

dc.contributor.authorDal Prá, K. J. [UNESP]
dc.contributor.authorLemos, C. A.A. [UNESP]
dc.contributor.authorOkamoto, R. [UNESP]
dc.contributor.authorSoubhia, A. M.P. [UNESP]
dc.contributor.authorPellizzer, E. P. [UNESP]
dc.date.accessioned2018-12-11T17:08:33Z
dc.date.available2018-12-11T17:08:33Z
dc.date.issued2017-02-01
dc.identifierhttp://dx.doi.org/10.1016/j.ijom.2016.10.009
dc.identifier.citationInternational Journal of Oral and Maxillofacial Surgery, v. 46, n. 2, p. 151-156, 2017.
dc.identifier.issn1399-0020
dc.identifier.issn0901-5027
dc.identifier.urihttp://hdl.handle.net/11449/173967
dc.description.abstractThis systematic review evaluated the efficacy of the morning fasting serum C-terminal telopeptide (CTX) test in predicting the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ). A comprehensive search of studies published up to March 2016, and listed in the PubMed/MEDLINE, Web of Science, and Cochrane Library databases, was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. This review has been registered in the PROSPERO international prospective register of systematic reviews (CRD42016036717). The search identified 542 publications; eight studies were finally deemed eligible for inclusion according to the study criteria. These studies included a total 1442 patients (mean age 66.7 years). The most prescribed drug was alendronate, with osteoporosis being the most frequent indication for the prescription of bisphosphonates. Tooth extraction was the most common trigger for BRONJ. Of all patients evaluated after bisphosphonate treatment, only 24 (1.7%) developed BRONJ. All eight of the selected studies found that CTX levels were not predictive of the development of BRONJ. In conclusion, this systematic review indicates that the CTX test has no predictive value in determining the risk of osteonecrosis in patients taking bisphosphonates.en
dc.format.extent151-156
dc.language.isoeng
dc.relation.ispartofInternational Journal of Oral and Maxillofacial Surgery
dc.sourceScopus
dc.subjectbisphosphonates
dc.subjectC-terminal telopeptide
dc.subjectCTX
dc.subjectosteonecrosis
dc.subjectsystematic review
dc.titleEfficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic reviewen
dc.typeResenha
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.description.affiliationDepartment of Pathology and Clinical Propaedeutics Araçatuba Dental School São Paulo State University (UNESP)
dc.description.affiliationDepartment of Dental Materials and Prosthodontics Araçatuba Dental School São Paulo State University (UNESP)
dc.description.affiliationDepartment of Surgery and Integrated Clinics Araçatuba Dental School São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Pathology and Clinical Propaedeutics Araçatuba Dental School São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Dental Materials and Prosthodontics Araçatuba Dental School São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Surgery and Integrated Clinics Araçatuba Dental School São Paulo State University (UNESP)
dc.identifier.doi10.1016/j.ijom.2016.10.009
dc.rights.accessRightsAcesso aberto
dc.identifier.scopus2-s2.0-85006942325
dc.identifier.file2-s2.0-85006942325.pdf
unesp.author.orcid0000-0002-5035-7011[1]
dc.relation.ispartofsjr1,137
Localize o texto completo

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record